Insight Guru Inc.
10/29/2026 | Press release | Distributed by Public on 10/29/2026 03:32
Market Movers | Winners: AXGN, KIDS, PRME | Losers: BCAX, INBX, FFIV
The S&P 500 gained 0.3% on Wednesday, October 28, while the Nasdaq-100 rose 0.5% and the Dow Jones Industrial Average inched up 0.2%. The S&P 500 is now down 0.2% over five trading days and up 1.0% over the past month.
Within the Trefis coverage universe, 2,342 stocks rose and 1,736 fell. Axogen (AXGN) gained 31.5% to lead the day, while Bicara Therapeutics (BCAX) fell 44.2%, the weakest showing.
Wednesday's Market Winners
The 10 US-listed stocks in the Trefis coverage universe worth at least $300 million with the highest returns on Wednesday:
| # | Ticker | Company Name |
1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | AXGN | Axogen | 31.5% | 50.5% |
| 2 | KIDS | OrthoPediatrics | 29.3% | 73.4% |
| 3 | PRME | Prime Medicine | 23.2% | 54.5% |
| 4 | REPL | Replimune | 23.1% | n/a |
| 5 | DNA | Ginkgo Bioworks | 18.2% | 60.3% |
| 6 | EMAT | Evolution Metals & Technologies | 17.5% | n/a |
| 7 | VRT | Vertiv | 16.5% | 50.1% |
| 8 | GENB | Generate Biomedicines | 16.4% | n/a |
| 9 | FWRD | Forward Air | 15.9% | -29.8% |
| 10 | BLCO | Bausch & Lomb | 15.8% | 19.4% |
Wednesday's Market Losers
And the 10 US-listed stocks in the Trefis coverage universe worth at least $300 million with the lowest returns on Wednesday:
| # | Ticker | Company Name |
1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics | -44.2% | -42.0% |
| 2 | INBX | Inhibrx Biosciences | -23.4% | -7.2% |
| 3 | FFIV | F5 | -20.4% | 43.2% |
| 4 | RAPP | Rapport Therapeutics | -18.3% | -25.8% |
| 5 | LSTR | Landstar System | -17.8% | -1.4% |
| 6 | BBNX | Beta Bionics | -16.5% | -41.4% |
| 7 | ENPH | Enphase Energy | -16.0% | -22.0% |
| 8 | GERN | Geron | -15.8% | -26.6% |
| 9 | LPLA | LPL Financial | -15.2% | -24.4% |
| 10 | SLS | SELLAS Life Sciences | -14.7% | 175.3% |
Which Of Wednesday's Movers Were Already On A Run?
Bicara Therapeutics (BCAX) added to a longer slide: after Wednesday's 44.2% decline, the stock is down 47.4% over the past month, and it was already down 5.8% before Wednesday.
The 23.2% gain in Prime Medicine (PRME) on Wednesday was not a one-off: the stock is up 73.5% over the past month, and up 40.8% over the sessions before Wednesday.
Movers Over The Last Week
Widening the window to five trading days, these are the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name |
1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | EAF | GrafTech International | 63.5% | -21.5% |
| 2 | SGRY | Surgery Partners | 50.9% | 50.4% |
| 3 | PRME | Prime Medicine | 40.7% | 54.5% |
| 4 | QSI | Quantum-Si | 39.8% | 56.4% |
| 5 | ENVX | Enovix | 38.6% | -51.8% |
| 6 | REPL | Replimune | 37.0% | n/a |
| 7 | AXGN | Axogen | 35.0% | 50.5% |
| 8 | TKNO | Alpha Teknova | 34.4% | 106.8% |
| 9 | DNA | Ginkgo Bioworks | 33.1% | 60.3% |
| 10 | PACB | Pacific Biosciences of California | 32.2% | 51.3% |
Losers
| # | Ticker | Company Name |
1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics | -45.5% | -42.0% |
| 2 | AVTX | Avalo Therapeutics | -41.9% | -60.8% |
| 3 | ORIC | ORIC Pharmaceuticals | -32.9% | 13.7% |
| 4 | CORT | Corcept Therapeutics | -25.8% | 147.9% |
| 5 | INBX | Inhibrx Biosciences | -25.4% | -7.2% |
| 6 | CRS | Carpenter Technology | -23.9% | -10.9% |
| 7 | SLM | SLM | -22.4% | -33.4% |
| 8 | ENPH | Enphase Energy | -21.9% | -22.0% |
| 9 | INOD | Innodata | -21.3% | -6.5% |
| 10 | KALU | Kaiser Aluminum | -21.0% | 7.5% |
Movers Over The Last Month
And over the last 21 trading days, the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name |
1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | NAUT | Nautilus Biotechnology | 135.2% | 64.6% |
| 2 | BMBL | Bumble | 131.9% | 66.9% |
| 3 | BRZE | Braze | 97.8% | 33.5% |
| 4 | QSI | Quantum-Si | 79.5% | 56.4% |
| 5 | PRME | Prime Medicine | 73.5% | 54.5% |
| 6 | SGRY | Surgery Partners | 61.3% | 50.4% |
| 7 | MYGN | Myriad Genetics | 56.7% | 7.8% |
| 8 | DXC | DXC Technology | 55.8% | 9.8% |
| 9 | PACB | Pacific Biosciences of California | 54.6% | 51.3% |
| 10 | NTSK | Netskope | 53.6% | 51.2% |
Losers
| # | Ticker | Company Name |
1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | AVTX | Avalo Therapeutics | -54.3% | -60.8% |
| 2 | NUAI | New Era Energy & Digital | -50.7% | 13.7% |
| 3 | FMC | FMC | -50.4% | -67.1% |
| 4 | BCAX | Bicara Therapeutics | -47.4% | -42.0% |
| 5 | SECZ | Securitize | -47.4% | n/a |
| 6 | AVBP | ArriVent BioPharma | -46.8% | -21.8% |
| 7 | CIFR | Cipher Digital | -46.3% | -39.9% |
| 8 | UNIT | Uniti | -43.3% | -30.7% |
| 9 | EMAT | Evolution Metals & Technologies | -42.3% | n/a |
| 10 | CBRS | Cerebras Systems | -42.3% | n/a |
Volatility Is The Cost Of Owning Stocks. Concentration Makes It A Bill
Every name on these lists made a move big enough to notice. A diversified holder reads that as noise; a concentrated holder feels it as real money. The difference is not the stock, it is the portfolio around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb bad days, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Let the movers list remind you why diversification exists.
Insight Guru Inc. published this content on October 29, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 29, 2026 at 09:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]